{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/whitlow-staphylococcal-herpetic/prescribing-information/erythromycin/","result":{"pageContext":{"chapter":{"id":"2a50e932-9f92-5a94-a8e5-aab1ee400b9d","slug":"erythromycin","fullItemName":"Erythromycin","depth":2,"htmlHeader":"<!-- begin field b6180978-196d-4fe8-aeae-cc8253f08453 --><h2>Erythromycin</h2><!-- end field b6180978-196d-4fe8-aeae-cc8253f08453 -->","summary":"","htmlStringContent":"<!-- begin item f27f161c-1b7e-47e3-83ed-0ad905cfc3a6 --><!-- end item f27f161c-1b7e-47e3-83ed-0ad905cfc3a6 -->","topic":{"id":"ac1c1826-f21a-5abd-8e92-1e2db8ea28ea","topicId":"f989f159-ab30-4d16-b9df-b534a9fd4192","topicName":"Whitlow (staphylococcal and herpetic)","slug":"whitlow-staphylococcal-herpetic","lastRevised":"Last revised in January 2021","chapters":[{"id":"8442fc1d-a788-50ac-a15a-9c2c91e8589b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"895f3b40-8720-5843-8910-fe1b288857a8","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7e4ec3c7-b080-5717-b1c3-0003acba46e5","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"7c70fe97-728d-5bc4-94c2-1996b37ee0f9","slug":"changes","fullItemName":"Changes"},{"id":"4889bd92-0b32-558d-8390-80d27fbcce73","slug":"update","fullItemName":"Update"}]},{"id":"1a79ca57-c8cc-5044-ac68-5d220bab1460","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"684fde23-e839-56ff-8b7f-8e6863b2c42d","slug":"goals","fullItemName":"Goals"},{"id":"97b35971-df6d-5ecb-a631-dfcf580e1fa9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"12181a78-1b8d-58b4-884a-8930d15cf654","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"521ae353-eea7-5e2f-bd0e-b292540b72eb","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"87054726-2905-5ac0-b369-92e5fd68a177","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"2b6dffce-588f-532a-9776-7e3ff32005ee","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"2d957194-aa56-5cb7-98aa-cb3d8f988743","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f0191f08-fb2e-5c5b-957c-8a190d5b4539","slug":"definition","fullItemName":"Definition"},{"id":"b8b2a1f1-fbc7-5b8f-a5c4-c0e9409d566f","slug":"causes","fullItemName":"Causes"},{"id":"c7287d38-e377-5d65-9c4f-3201369e0213","slug":"prevalence","fullItemName":"Prevalence"},{"id":"adc749af-b4d0-50c9-9996-b470b8f76613","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"d632b72f-6e73-58ee-9d8d-21b6101f6394","slug":"prognosis","fullItemName":"Prognosis"},{"id":"faed0075-1878-5f17-abc9-9316eaa064e7","slug":"complications","fullItemName":"Complications"}]},{"id":"96e4a200-e348-5fab-89e2-f0ba789b7b72","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"910097a7-71be-5c13-949e-0be7c045df35","slug":"diagnosis-of-whitlow","fullItemName":"Diagnosis of whitlow"},{"id":"6f468174-fafe-579c-90f9-500f22e70e17","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"8ac8a269-e748-5e7e-9b74-8fb5661d1ae5","fullItemName":"Management","slug":"management","subChapters":[{"id":"ac7fabf7-d7b7-5fb2-a0a6-1d28e040e2c8","slug":"staphylococcal-whitlow","fullItemName":"Scenario: Staphylococcal whitlow"},{"id":"bde8ed40-6fd8-505e-86bb-d75eac34743f","slug":"herpetic-whitlow","fullItemName":"Scenario: Herpetic whitlow"}]},{"id":"5d7afad5-ae43-5c2e-8ecf-6df00603ca01","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"ae3b006b-c4df-5e15-aee8-5ac6c019923f","slug":"aciclovir","fullItemName":"Aciclovir"},{"id":"46185de6-35ef-5e34-a1fd-e0d1463c538e","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"2a50e932-9f92-5a94-a8e5-aab1ee400b9d","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"0ad07f56-519a-59d6-90bc-6b6d6081e6ab","slug":"flucloxacillin","fullItemName":"Flucloxacillin"}]},{"id":"98ea0d83-9b18-58b4-aa73-7a50d72e15ba","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4dd77db6-a4e1-5304-8a06-196e7628f612","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0191f79d-0e03-554c-b0bd-4b592d452f4a","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3e95c155-472c-52d0-9098-a797cec2ad27","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"f39c5716-7472-576a-be8f-7d705a0dc4dd","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"73c24405-a40a-51ba-ac01-8dd957f7c657","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7005b3b9-63e2-5222-840e-73155dac338e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"18dd81bb-78d7-57f1-9fc9-24aa775b3c9d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"5d7afad5-ae43-5c2e-8ecf-6df00603ca01","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"a607a828-e492-5dad-914f-5abbdce7c94b","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field 9dd3bc36-93c2-46eb-82ce-fab7f36c79c9 --><h3>What dose of erythromycin should I prescribe?</h3><!-- end field 9dd3bc36-93c2-46eb-82ce-fab7f36c79c9 -->","summary":"","htmlStringContent":"<!-- begin item d07ddb43-adb9-4804-8f97-72fec05a6966 --><!-- begin field 51c6e5af-a728-4e8c-a831-4f882c517c50 --><ul><li>Erythromycin doses:</li><ul><li>Adults and children older than 8 years of age — 250 mg to 500 mg, four times a day for 7 days.</li><li>Children 2–8 years of age — 250 mg, four times a day for 7 days (dose can be doubled in severe infection).</li><li>Children 1 month to 2 years of age — 125 mg, four times a day for 7 days (dose can be doubled in severe infection).</li></ul></ul><p>  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">BNF for Children, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">PHE, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">BNF 71, 2016</a>]</p><!-- end field 51c6e5af-a728-4e8c-a831-4f882c517c50 --><!-- end item d07ddb43-adb9-4804-8f97-72fec05a6966 -->","subChapters":[]},{"id":"def77595-84b4-543e-98d9-ca1a81668861","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 993be1ec-3c9e-4bf7-8a17-3247b32eaaaa --><h3>What are the contraindications and cautions for erythromycin?</h3><!-- end field 993be1ec-3c9e-4bf7-8a17-3247b32eaaaa -->","summary":"","htmlStringContent":"<!-- begin item 02209d8b-05d3-4ad1-a589-99b646679dcb --><!-- begin field 922e4d60-9677-4f96-a5dd-ef394d8391b3 --><ul><li><strong>Do not prescribe erythromycin</strong> to people with:<ul><li>Porphyria or a known hypersensitivity to erythromycin.</li><li>A history of QT interval prolongation or ventricular cardiac arrhythmia.</li><li>Conditions that predispose to QT interval prolongation such as electrolyte disturbances and people taking drugs that prolong the QT interval.</li></ul></li><li><strong>Prescribe erythromycin with caution</strong> in people with:<ul><li>Impaired hepatic function (or people concomitantly receiving potentially hepatotoxic drugs) — erythromycin is principally excreted by the liver. </li><li>Renal impairment — give a maximum of 1.5 g daily in severe renal impairment due to the risk of ototoxicity. </li><li>Myasthenia gravis — macrolide antibiotics may aggravate weakness symptoms of people with myasthenia gravis.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">ABPI, 2015c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">BNF 71, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">MHRA, 2020</a>]</p><!-- end field 922e4d60-9677-4f96-a5dd-ef394d8391b3 --><!-- end item 02209d8b-05d3-4ad1-a589-99b646679dcb -->","subChapters":[]},{"id":"205d82d4-fa97-528a-82e3-6b38c4c394c5","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 9a678e96-65a1-4b8d-bd41-553a1f5dda14 --><h3>What are the adverse effects of erythromycin?</h3><!-- end field 9a678e96-65a1-4b8d-bd41-553a1f5dda14 -->","summary":"","htmlStringContent":"<!-- begin item 65ad1860-5f52-46de-9f28-3e1ceb7d2b3e --><!-- begin field 0d90277c-7044-4a90-81ec-7e003366b11b --><ul><li>Gastrointestinal adverse effects such as nausea, vomiting, and diarrhoea, are common in people taking erythromycin.<ul><li>Consider pseudomembranous colitis if a person develops severe diarrhoea during or after treatment with erythromycin.</li><li>Pseudomembranous colitis is an acute, exudative colitis caused by <em>Clostridium difficile</em>, a Gram-positive toxin-releasing bacillus. It often follows antibiotic treatment. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li>Hepatic dysfunction including increased liver enzymes and cholestatic hepatitis (with or without jaundice) has been rarely reported with this drug.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">ABPI, 2015c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">BNF 71, 2016</a>]</p><!-- end field 0d90277c-7044-4a90-81ec-7e003366b11b --><!-- end item 65ad1860-5f52-46de-9f28-3e1ceb7d2b3e -->","subChapters":[]},{"id":"33cc8ee4-4642-5a4a-8725-b057919fa0f9","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 4d27f511-424d-43e0-941f-f7ba126cc543 --><h3>What are the important drug interactions with erythromycin?</h3><!-- end field 4d27f511-424d-43e0-941f-f7ba126cc543 -->","summary":"","htmlStringContent":"<!-- begin item 89969122-c208-4417-9d60-2c129ea5fe7f --><!-- begin field aacef663-2aaf-41e0-82b6-1bb6851ee720 --><ul><li><strong>Drug interactions with erythromycin include:</strong><ul><li><strong>Tolterodine, mizolastine, amisulpride, domperidone, ergotamine, dihydroergotamine, or pimozide </strong><strong>—</strong> concurrent administration with erythromycin is contraindicated.</li><li><strong>Cimetidine</strong> <strong>—</strong> monitor concurrent use closely as a dose reduction of erythromycin may be necessary. Cimetidine may inhibit the metabolism of erythromycin, leading to an increased plasma concentration.</li><li><strong>Calcium channel blockers (CCBs)</strong> <strong>—</strong> due to an increased risk of hypotension, caution is advised with the concurrent use of erythromycin and CCBs metabolised by CYP3A4 (such as verapamil).</li><li><strong>Colchicine</strong><strong> —</strong> avoid concurrent use if possible. Colchicine toxicity has been reported following concomitant use with erythromycin.</li><li><strong>Carbamazepine</strong> <strong>—</strong> monitor carbamazepine levels within 3–5 days of starting erythromycin and adjust the dose accordingly. Erythromycin can increase carbamazepine levels, causing carbamazepine toxicity (which may present as nausea and vomiting, ataxia, and drowsiness).</li><li><strong>Drugs that prolong the QT interval</strong><strong> —</strong> if possible, avoid giving erythromycin to a person who is already taking a drug that can potentially prolong the QT interval.</li><li><strong>Statins</strong> <strong>—</strong> there is an increased risk of myopathy.<ul><li>For simvastatin — do not prescribe erythromycin to a person taking simvastatin. Consider temporarily stopping simvastatin during short-term treatment with erythromycin. </li><li>For atorvastatin — avoid concurrent use with erythromycin if possible. Consider temporarily stopping atorvastatin during short-term treatment with erythromycin. If concurrent use cannot be avoided, prescribe the lowest starting dose of atorvastatin (10 mg), and advise the person to report any muscle pain, tenderness, or weakness.</li><li>For pravastatin — prescribe erythromycin with caution and advise the person to seek medical advice if they experience symptoms of myopathy (for example muscle pain, tenderness, or weakness).</li><li>Other statins — clinically significant interaction with erythromycin is not expected for rosuvastatin and fluvastatin. Nevertheless, advise the person to report any muscle pain, tenderness, or weakness. </li></ul></li><li><strong>Theophylline</strong> <strong>—</strong> consider using clarithromycin (in preference to erythromycin) as clarithromycin normally causes only modest (clinically unimportant) increases in theophylline levels.<ul><li>Concurrent use of erythromycin with high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity (which may present as palpitations, nausea, tremor, and headache). If this is suspected, reduce the dose of theophylline. </li><li>Concurrent treatment may also result in a significant decrease in erythromycin serum concentrations, leading to sub-therapeutic concentrations of erythromycin.</li></ul></li><li><strong>Rivaroxaban </strong>— erythromycin may increase levels of rivaroxaban, increasing the risk of bleeding. </li><li><strong>Warfarin</strong> <strong>—</strong> monitor the international normalized ratio (INR) when both drugs are used (particularly in elderly people), and adjust the warfarin dose accordingly. Erythromycin may enhance the effect of warfarin; this is an established but unpredictable interaction.</li><li><strong>Zopiclone</strong> <strong>—</strong> monitor concurrent use. Erythromycin has been reported to decrease the clearance of zopiclone and this may lead to an increase in the effects of zopiclone. </li><li><strong>Oral hormonal contraception</strong> <strong>—</strong> additional contraceptive precautions are not required during or after courses of erythromycin.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/\">Contraception - assessment</a>.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">FSRH, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">ABPI, 2014c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">ABPI, 2015c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">Preston, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">MHRA, 2020</a>]</p><!-- end field aacef663-2aaf-41e0-82b6-1bb6851ee720 --><!-- end item 89969122-c208-4417-9d60-2c129ea5fe7f -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}